• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Transfusion . ABO blood type association with SARS-CoV-2 infection mortality: A single-center population in New York City

tetano

Editor, Senior Moderator
Transfusion


. 2021 Mar 5.
doi: 10.1111/trf.16339. Online ahead of print.
ABO blood type association with SARS-CoV-2 infection mortality: A single-center population in New York City


James Szymanski[SUP] #[/SUP][SUP] 1 [/SUP], Laurel Mohrmann[SUP] #[/SUP][SUP] 2 [/SUP], Jamal Carter[SUP] 1 [/SUP], Randin Nelson[SUP] 1 [/SUP], Sweta Chekuri[SUP] 2 [/SUP], Andrei Assa[SUP] 2 [/SUP], Brian Spund[SUP] 2 [/SUP], Morayma Reyes-Gil[SUP] 1 [/SUP], Joan Uehlinger[SUP] 1 [/SUP], Sarah Baron[SUP] #[/SUP][SUP] 2 [/SUP], Monika Paroder[SUP] #[/SUP][SUP] 1 [/SUP]



Affiliations

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a variable clinical course with significant mortality. Early reports suggested higher rates of SARS-CoV-2 infection in patients with type A blood and enrichment of type A individuals among COVID-19 mortalities.
Study design and methods: The study includes all patients hospitalized or with an emergency department (ED) visit who were tested for SARS-CoV-2 between March 10, 2020 and June 8, 2020 and had a positive test result by nucleic acid test (NAT) performed on a nasopharyngeal swab specimen. A total of 4968 patients met the study inclusion criteria, with a subsequent 23.1% (n = 1146/4968) all-cause mortality rate in the study cohort. To estimate overall risk by ABO type and account for the competing risks of in-hospital mortality and discharge, we calculated the cumulative incidence function (CIF) for each event. Cause-specific hazard ratios (csHRs) for in-hospital mortality and discharge were analyzed using multivariable Cox proportional hazards models.
Results: Type A blood was associated with the increased cause-specific hazard of death among COVID-19 patients compared to type O (HR = 1.17, 1.02-1.33, p = .02) and type B (HR = 1.32,1.10-1.58, p = .003).
Conclusions: Our study shows that ABO histo-blood group type is associated with the risk of in-hospital death in COVID-19 patients, warranting additional inquiry. Elucidating the mechanism behind this association may reveal insights into the susceptibility and/or immunity to SARS-CoV-2.

Keywords: ABO; SARS-CoV-2.
 
Back
Top Bottom